ArrowheadPharma's banner

ArrowheadPharma

@ArrowheadPharma • 3,956 subscribers

Arrowhead Pharmaceuticals develops medicines that treat intractable diseases by silencing the genes that cause them.

Shorts

Breaking News: We’re pleased to announce positive topline results, with our Phase 3 SHASTA-3 and SHASTA-4 studies achieving the primary endpoint and all secondary endpoints in patients living with severe hypertriglyceridemia (sHTG). Learn more:

Breaking News: We’re pleased to announce positive topline results, with our Phase 3 SHASTA-3 and SHASTA-4 studies achieving the primary endpoint and all secondary endpoints in patients living with severe hypertriglyceridemia (sHTG). Learn more:

22,396 просмотров

We’ve entered a strategic partnership with Madrigal Pharmaceuticals to advance an RNAi therapeutic for MASH, combining the precision of Arrowhead’s TRiM™ platform with Madrigal’s liver disease expertise. Read the full announcement:

We’ve entered a strategic partnership with Madrigal Pharmaceuticals to advance an RNAi therapeutic for MASH, combining the precision of Arrowhead’s TRiM™ platform with Madrigal’s liver disease expertise. Read the full announcement:

14,563 просмотров

🚨 FDA APPROVED! Arrowhead’s therapy to lower triglycerides in adults with Familial Chylomicronemia Syndrome (FCS) offers new hope for patients & families facing this #RareDisease. A major step forward in RNAi innovation. #FCS #FDAApproval

🚨 FDA APPROVED! Arrowhead’s therapy to lower triglycerides in adults with Familial Chylomicronemia Syndrome (FCS) offers new hope for patients & families facing this #RareDisease. A major step forward in RNAi innovation. #FCS #FDAApproval

18,539 просмотров

Videos

Anya Rossi

sweetdream.ai

SweetDream.ai•Sponsored•Livecam

Watch Anya Live

Anya is streaming live right now! Join her private show and enjoy exclusive content.

Exclusive private shows

1.2k viewers online

Private Show

Join now for exclusive access

Free preview available • Premium content

Today we announced interim Phase 1/2a clinical data for ARO-MAPT. The results represent an important step in clinical validation of our TRiM platform for delivering siRNA to the central nervous system. Join today’s webinar to learn more:

Today we announced interim Phase 1/2a clinical data for ARO-MAPT. The results represent an important step in clinical validation of our TRiM platform for delivering siRNA to the central nervous system. Join today’s webinar to learn more:

ArrowheadPharma

26,361 просмотров • 1 месяц назад

Больше нет контента для загрузки